AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6612232 — intervention group
Group type: COMPARATOR
Intervention: Conventional vasectomy by transection and ligation
Number of subjects: 68
Study 30776996 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 13126
Study 30776996 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 13126
Study 30776996 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor and Aspirin
Number of subjects: 13126
Study 28815733 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome®)
Number of subjects: 12
Study 28815733 — intervention group
Group type: COMPARATOR
Intervention: Conventional amphotericin B (Fungizone®)
Number of subjects: 12
Study 26546476 — intervention group
Group type: EXPERIMENTAL
Intervention: Testimonial-based intervention on drowning risk
Number of subjects: 280
Study 26546476 — intervention group
Group type: COMPARATOR
Intervention: Dog-bite risk (control)
Number of subjects: 280
Study 24257149 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 2039
Study 24257149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2039
Study 22826530 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.5% (10 mL)
Number of subjects: 14
Study 22826530 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% with dexmedetomidine 1 μg/kg (10 mL)
Number of subjects: 14
Study 20088935 — intervention group
Group type: EXPERIMENTAL
Intervention: YM150 5 mg
Number of subjects: 1017
Study 20088935 — intervention group
Group type: EXPERIMENTAL
Intervention: YM150 10 mg
Number of subjects: 1017
Study 20088935 — intervention group
Group type: EXPERIMENTAL
Intervention: YM150 30 mg
Number of subjects: 1017
Study 20088935 — intervention group
Group type: EXPERIMENTAL
Intervention: YM150 60 mg
Number of subjects: 1017
Study 20088935 — intervention group
Group type: EXPERIMENTAL
Intervention: YM150 120 mg
Number of subjects: 1017
Study 20088935 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin (40 mg)
Number of subjects: 1017
Study 17611320 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL‐11 (1.5mg/d)
Number of subjects: 24
Study 17611320 — intervention group
Group type: COMPARATOR
Intervention: Control group (symptomatic treatment)
Number of subjects: 24
Study 16076946 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/d)
Number of subjects: 30
Study 12084136 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief interventions (5 to 60 minutes duration)
Number of subjects: 554
Study 12084136 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control condition
Number of subjects: 554
Study 10463404 — intervention group
Group type: EXPERIMENTAL
Intervention: Drop test with varying test solutions
Number of subjects: 63
Study 10463404 — intervention group
Group type: EXPERIMENTAL
Intervention: Drop test
Number of subjects: 63
Study 10463404 — intervention group
Group type: EXPERIMENTAL
Intervention: Drop test with increased viscosity of test solution
Number of subjects: 63
Study 8531592 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin 100 micrograms bolus
Number of subjects: 17
Study 8531592 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin 250 micrograms bolus
Number of subjects: 17
Study 8531592 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of bolus (250 micrograms) and infusion (250 micrograms/h for 65 min) of somatostatin
Number of subjects: 17
Study 2083047 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthrinse containing 0.03% triclosan and 0.25% copolymer (Gantrez)
Number of subjects: 60
Study 2083047 — intervention group
Group type: COMPARATOR
Intervention: Water placebo mouthrinse
Number of subjects: 60
Study 2083047 — intervention group
Group type: COMPARATOR
Intervention: Plax antiplaque prebrushing dental rinse
Number of subjects: 60
Study 29902225 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal rich in rapeseed oil
Number of subjects: 10
Study 29902225 — intervention group
Group type: COMPARATOR
Intervention: Meal rich in palm oil
Number of subjects: 10
Study 26814251 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative method of local anesthesia injection
Number of subjects: 127
Study 26814251 — intervention group
Group type: COMPARATOR
Intervention: Traditional method of local anesthesia injection
Number of subjects: 127
Study 26814251 — intervention group
Group type: COMPARATOR
Intervention: No local anesthetic
Number of subjects: 127
Study 26814251 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment needle size
Number of subjects: 127
Study 26814251 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain at one inch of treatment needle insertion
Number of subjects: 127
Study 26814251 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline pain
Number of subjects: 127
Study 25123560 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual diagnosis by operating urologist
Number of subjects: 311
Study 25123560 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual diagnosis by operating urologist (specifically for muscle invasive cancer)
Number of subjects: 311
Study 22156231 — intervention group
Group type: EXPERIMENTAL
Intervention: HEALTHY physical education intervention
Number of subjects: 21
Study 20570604 — intervention group
Group type: EXPERIMENTAL
Intervention: Unloaded arm cycling exercise
Number of subjects: 10
Study 20570604 — intervention group
Group type: EXPERIMENTAL
Intervention: Unloaded leg cycling exercise
Number of subjects: 10
Study 20570604 — intervention group
Group type: COMPARATOR
Intervention: Control (quiet sitting)
Number of subjects: 10
Study 17696680 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash-based incentives ($50 and $100)
Number of subjects: 12
Study 17696680 — intervention group
Group type: COMPARATOR
Intervention: Goods-based incentives (vouchers)
Number of subjects: 12
Study 17696680 — intervention group
Group type: COMPARATOR
Intervention: $100 checks (cash-based incentives)
Number of subjects: 12
Study 15614703 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone-Azithromycin
Number of subjects: 369
Study 15614703 — intervention group
Group type: COMPARATOR
Intervention: TMP-SMZ
Number of subjects: 369
Study 12394202 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal budesonide, applied to each nostril, once daily for eight weeks
Number of subjects: 145
Study 9934299 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual 15-minute educational presentations based on academic detailing
Number of subjects: 59
Study 9934299 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 59
Study 8610775 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of intravaginal prostaglandin E2 gel for 5 consecutive days
Number of subjects: 100
Study 8610775 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 consecutive days
Number of subjects: 100
Study 2191763 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (2500 cGy over 5 to 7 days)
Number of subjects: 849
Study 2191763 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 849
Study 367574 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMF (Cyclophosphamide, Adriamycin, Methotrexate, 5-Fluorouracil)
Number of subjects: 78
Study 367574 — intervention group
Group type: COMPARATOR
Intervention: CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil)
Number of subjects: 78
Study 367574 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF with Adriamycin at progression
Number of subjects: 78
Study 31055568 — intervention group
Group type: EXPERIMENTAL
Intervention: MBP + OABP group
Number of subjects: 254
Study 31055568 — intervention group
Group type: COMPARATOR
Intervention: OABP alone group
Number of subjects: 254
Study 28836895 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine
Number of subjects: 0
Study 28836895 — intervention group
Group type: EXPERIMENTAL
Intervention: CHIP‐CE:PRF Achievement and Risk Avoidance
Number of subjects: 0
Study 28836895 — intervention group
Group type: COMPARATOR
Intervention: Guanfacine extended-release
Number of subjects: 0
Study 28836895 — intervention group
Group type: COMPARATOR
Intervention: Osmotic‐release methylphenidate
Number of subjects: 0
Study 28836895 — intervention group
Group type: COMPARATOR
Intervention: Atomoxetine
Number of subjects: 0
Study 28291972 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentative rTMS
Number of subjects: 93
Study 28291972 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 93
Study 26501260 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcosine (2 grams daily)
Number of subjects: 50
Study 26501260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 24005198 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and plate fixation
Number of subjects: 200
Study 21496800 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind/body program (MB)
Number of subjects: 143
Study 21496800 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 143
Study 19781471 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration of residual lens epithelial cells (Group A)
Number of subjects: 2
Study 19781471 — intervention group
Group type: COMPARATOR
Intervention: No aspiration of residual lens epithelial cells (Group B)
Number of subjects: 2
Study 17590215 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 311
Study 17590215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study 15554753 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate (clodronate disodium, Bonefos)
Number of subjects: 0
Study 11881575 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga training for 1 hour 15 minutes per day, 7 days a week
Number of subjects: 20
Study 11881575 — intervention group
Group type: COMPARATOR
Intervention: Physical training for 1 hour 15 minutes per day, 7 days a week
Number of subjects: 20
Study 9693934 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (M; n = 15)
Number of subjects: 30
Study 9693934 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P; n = 15)
Number of subjects: 30
Study 7835855 — intervention group
Group type: EXPERIMENTAL
Intervention: Capitated funding program
Number of subjects: 422
Study 7835855 — intervention group
Group type: COMPARATOR
Intervention: Standard fee‐based services (Control)
Number of subjects: 422
Study 17171863 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol, 2.5 mg/kg
Number of subjects: 16
Study 17171863 — intervention group
Group type: COMPARATOR
Intervention: Thiamylal, 4 mg/kg
Number of subjects: 16
Study 29575668 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (simple advice)
Number of subjects: 130
Study 29575668 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group dropped out)
Number of subjects: 130
Study 28963127 — intervention group
Group type: EXPERIMENTAL
Intervention: Light resistance exercise (30% 1RM)
Number of subjects: 15
Study 28963127 — intervention group
Group type: COMPARATOR
Intervention: Heavy resistance exercise (80% 1RM)
Number of subjects: 15
Study 28963127 — intervention group
Group type: EXPERIMENTAL
Intervention: Light resistance exercise (30% 1RM) and Heavy resistance exercise (80% 1RM)
Number of subjects: 15
Study 26223978 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise for 24 weeks
Number of subjects: 43
Study 26223978 — intervention group
Group type: COMPARATOR
Intervention: Control group (no regular exercise)
Number of subjects: 43
Study 23030403 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 7774
Study 23030403 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled
Number of subjects: 7774
Study 23030403 — intervention group
Group type: COMPARATOR
Intervention: Active-comparator
Number of subjects: 7774
Study 23030403 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled crossover
Number of subjects: 7774
Study 22027664 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC) administered in doses from 2250 to 3000 mg per day
Number of subjects: 0
Study 22027664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18453933 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfaculty registered nurses supervising high-fidelity human-patient simulation
Number of subjects: 0
Study 16532095 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (30 mg of elemental zinc/cap/day) for 3 months
Number of subjects: 101
Study 16532095 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 101
Study 15231905 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy and Adenoidectomy (T&A)
Number of subjects: 59
Study 15231905 — intervention group
Group type: COMPARATOR
Intervention: No surgery (observation)
Number of subjects: 59
Study 11361230 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbitol (250 mg) 3 times a day before meals
Number of subjects: 88
Study 11361230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 9231150 — intervention group
Group type: EXPERIMENTAL
Intervention: Generating information
Number of subjects: 0
Study 9231150 — intervention group
Group type: COMPARATOR
Intervention: Reading information
Number of subjects: 0
Study 7970073 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical CT infection
Number of subjects: 80
Study 7970073 — intervention group
Group type: COMPARATOR
Intervention: Careful screening during pregnancy
Number of subjects: 80
Study 3310620 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis without anticoagulation
Number of subjects: 49
Study 29888613 — intervention group
Group type: EXPERIMENTAL
Intervention: CRD-Pre
Number of subjects: 0
Study 29888613 — intervention group
Group type: EXPERIMENTAL
Intervention: RCT
Number of subjects: 0
Study 29888613 — intervention group
Group type: EXPERIMENTAL
Intervention: RDD
Number of subjects: 0
Study 29888613 — intervention group
Group type: COMPARATOR
Intervention: Basic RDD
Number of subjects: 0
Study 27367436 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low nicotine cigarettes (VLNCs; 0.4 mg nicotine/g tobacco) for 6 weeks
Number of subjects: 242
Study 24102480 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 26
Study 24102480 — intervention group
Group type: COMPARATOR
Intervention: Acupressure and massage (Control)
Number of subjects: 26
Study 22082281 — intervention group
Group type: EXPERIMENTAL
Intervention: Freshest available compatible RBCs
Number of subjects: 51
Study 20847993 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 22
Study 20847993 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study 18628485 — intervention group
Group type: EXPERIMENTAL
Intervention: EHCSS (electrically heated cigarette smoking system)
Number of subjects: 18
Study 18628485 — intervention group
Group type: COMPARATOR
Intervention: CC (conventional cigarette)
Number of subjects: 18
Study 18628485 — intervention group
Group type: COMPARATOR
Intervention: NS (no smoking)
Number of subjects: 18
Study 16816829 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (1 Hz at 110% of motor threshold) administered over the left dorso-lateral prefrontal cortex for 10 sessions.
Number of subjects: 33
Study 16816829 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS administered over the left dorso-lateral prefrontal cortex for 10 sessions.
Number of subjects: 33
Study 12932382 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate systemic therapy with oral chlorambucil 10 mg per day continuously
Number of subjects: 309
Study 12932382 — intervention group
Group type: COMPARATOR
Intervention: Observation with systemic therapy delayed until disease progression
Number of subjects: 309
Study 10190655 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapreotide (1.5 mg day(-1) s.c.) for 7 days
Number of subjects: 10
Study 10190655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7674883 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful exercise (ME) group - Tai Chi type program
Number of subjects: 135
Study 7674883 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity walking group (MW)
Number of subjects: 135
Study 7674883 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity walking group (LW)
Number of subjects: 135
Study 7674883 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity walking plus relaxation response group (LWR)
Number of subjects: 135
Study 7674883 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 135
Study 2502385 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (20 mg/day for adult)
Number of subjects: 190
Study 2502385 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (80 mg/day for adult)
Number of subjects: 190
Study 2502385 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (20 mg/day for adult) in patients with Lennox-Gastaut syndrome
Number of subjects: 190
Study 2502385 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (80 mg/day for adult) in patients with Lennox-Gastaut syndrome
Number of subjects: 190
Study 1106806 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension sutures tied loosely (over three fingers of the assistant's hand)
Number of subjects: 0
Study 1106806 — intervention group
Group type: COMPARATOR
Intervention: Tension sutures tied flush with the wound
Number of subjects: 0
Study 31916007 — intervention group
Group type: EXPERIMENTAL
Intervention: AYA
Number of subjects: 1135
Study 31916007 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-aged adults
Number of subjects: 1135
Study 31916007 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 1135
Study 31916007 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-aged men
Number of subjects: 1135
Study 31916007 — intervention group
Group type: EXPERIMENTAL
Intervention: AYA men
Number of subjects: 1135
Study 30763730 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg once daily)
Number of subjects: 29
Study 30763730 — intervention group
Group type: COMPARATOR
Intervention: Osimertinib plus Durvalumab (10 mg/kg every 2 weeks)
Number of subjects: 29
Study 28419124 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once a day
Number of subjects: 45
Study 28419124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 26123068 — intervention group
Group type: EXPERIMENTAL
Intervention: ARTEMIS+CM (n = 12)
Number of subjects: 21
Study 26123068 — intervention group
Group type: COMPARATOR
Intervention: CM-only (n = 9)
Number of subjects: 21
Study 26123068 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study 23612408 — intervention group
Group type: EXPERIMENTAL
Intervention: Neyromidin
Number of subjects: 40
Study 23612408 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 40
Study 21175914 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management program
Number of subjects: 0
Study 19782789 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 240
Study 19782789 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 240
Study 17712202 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pump (IABP)
Number of subjects: 33
Study 17712202 — intervention group
Group type: COMPARATOR
Intervention: No IABP
Number of subjects: 33
Study 14739127 — intervention group
Group type: EXPERIMENTAL
Intervention: tranexamic acid (2 g, n=8)
Number of subjects: 16
Study 14739127 — intervention group
Group type: COMPARATOR
Intervention: placebo (n=8)
Number of subjects: 16
Study 11434163 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet activation assessment at the onset of INS and after 2 weeks of therapy
Number of subjects: 24
Study 11434163 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of CD42b at the onset of INS
Number of subjects: 24
Study 11434163 — intervention group
Group type: COMPARATOR
Intervention: Comparison with healthy children (group B)
Number of subjects: 24
Study 10050266 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sucrose diet for one month (50 patients)
Number of subjects: 107
Study 10050266 — intervention group
Group type: COMPARATOR
Intervention: Usual diet for one month (55 patients)
Number of subjects: 107
Study 10050266 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sucrose diet (50 patients)
Number of subjects: 107
Study 8042724 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (50 mg intramuscularly before surgery, repeated at 4 and 10 hours)
Number of subjects: 26
Study 8042724 — intervention group
Group type: COMPARATOR
Intervention: Saline (intramuscularly)
Number of subjects: 26
Study 8042724 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (10 mg intravenously after assessing block height)
Number of subjects: 26
Study 3635599 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected music as a conditioning aid during prepared childbirth education
Number of subjects: 30
Study 3635599 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 30
Study 29572715 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-apical RV leads
Number of subjects: 743
Study 29572715 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-apical RV and apical LV leads
Number of subjects: 743
Study 29572715 — intervention group
Group type: COMPARATOR
Intervention: RV-LV lead sub-groups
Number of subjects: 743
Study 26756859 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate/severe CAC
Number of subjects: 7492
Study 26756859 — intervention group
Group type: COMPARATOR
Intervention: Nil/mild CAC
Number of subjects: 7492
Study 24983709 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 0
Study 22505276 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 0
Study 22505276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20528799 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position exclusively
Number of subjects: 112
Study 20528799 — intervention group
Group type: COMPARATOR
Intervention: Alternated between supine and prone position every third hour
Number of subjects: 112
Study 18947426 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral acidic and neutral oligosaccharides supplementation (20%/80%)
Number of subjects: 120